2011 Schedule
Wednesday, July 20

7:30 a.m.-5 p.m. Registration

8:30-10 a.m. Plenary session

PL-04 Plenary 4

PL-04-01 Cortical connectivity and sensory binding: A neurocognitive approach to the detection and assessment of Alzheimer's disease
William Heindel, Brown University, Providence, R.I., United States

PL-04-02 Diagnostic value of CSF biomarkers for (differential) dementia diagnosis
Sebastian Engelborghs, University of Antwerp, Antwerp, Belgium

PL-04-03 Tau Phosphorylation, Tau Aggregation, and Clinical Symptoms
Luc Buee, University of Lille, Lille, France

10-10:30 a.m. Break

10 a.m.-3 p.m. Exhibit Hall open

10:30 a.m.-12:30 p.m. Invited Symposia and Featured Research Sessions

S4-01 Biomarkers
Chairs: Wiesje van der Flier, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
Kaj Blennow, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

S4-01-01 Lessons From Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
Kaj Blennow, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

S4-01-02 Use of CSF Biomarkers in Clinical Trials: the ADNI Experience
Leslie Shaw, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pa., United States

S4-01-03 A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease
Sid O'Bryant, Texas Tech University Health Science Center, Lubbock, Texas, United States

S4-01-04 Progress in CSF Biomarker Discovery for Mild Cognitive Impairment and Alzheimer's Disease by Label-Free Quantitative Proteomics
Connie Jiménez, VU University Medical Center, Amsterdam, the Netherlands

S4-01-05 The 28-amino Acid Form of an APLP1-derived Abeta-like Peptide is a Surrogate Marker for Abeta42 Production
Okochi M, Psychiatry, Division of Internal Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

S4-01-06 CSF sPLA2:A New Biomarker of Neuroinflammation and Blood-CSF Barrier Impairment
Sonia Chalbot, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, N.Y., United States

S4-02 Disease Mechanisms
Chairs: Takaomi Saido, RIKEN Brain Science Institute, Wako, Japan
Maria Spillantini, University of Cambridge, Cambridge, United Kingdom

S4-02-01 APP/Tau Interaction and Axonal Transport
Lawrence Goldstein, Howard Hughes Medical Institute, University of California, San Diego School of Medicine, San Diego, Calif., United States

S4-02-02 Cholesterol and APP
Marie-Claude Potier, Centre de Recherche de l'ICM, Paris, France

S4-02-03 Tau and GSK3ß
Jean Pierre Brion, General Histology Laboratory, Neuroanatomy and Neuropathology, Université Libre de Bruxelles, Brussels, Belgium

S4-02-04 Alzheimer's Disease as Synaptopathy Including ADAM10
Monica di Luca, Laboratory of Pharmacology of Neurodegeneration, University of Milano Milano, Italy

S4-02-05 New Presenilin Hypothesis
Jie Shen, Brigham and Women's Hospital, Boston, Mass., United States

S4-02-06 Gene Therapy Utilizing Growth Factors
Mark Tuszynski, University of California, San Diego, La Jolla, Calif., United States

12:30-3 p.m.Poster presentations and lunch on your own

3-5 p.m. Oral presentations

6-10 p.m. Corporate sponsored symposia